Evidence map›Paper›PMID 37444415›Full record

ReviewCancers2023

Beyond PARP Inhibitors in Advanced Breast Cancer Patients with Germline

Marta Nerone, Lorenzo Rossi, Rosaria Condorelli, Vilma Ratti, Fabio Conforti, Antonella Palazzo, Rossella Graffeo

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. JCO precision oncology · 2025
    Trial
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Marta NeroneService of Medical Oncology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.
Lorenzo RossiService of Medical Oncology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.
Rosaria CondorelliService of Medical Oncology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.
Vilma RattiService of Medical Oncology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.ORCID 0009-0005-3246-8921
Fabio ConfortiOncology Unit, Humanitas Gavazzeni, 24125 Bergamo, Italy.
Antonella PalazzoComprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, 00168 Rome, Italy.ORCID 0000-0002-8371-7087
Rossella GraffeoService of Medical Oncology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.ORCID 0000-0002-4963-5432
Ente Ospedaliero Cantonale · CHAgostino Gemelli University Polyclinic · ITHumanitas Gavazzeni · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We explored the outcomes of germline

Indexed as

advanced breast cancerCDK4/6 inhibitorsgermline BRCA1/2 mutationsHER2-lowpathogenic/likely pathogenic variantsPi3Ka inhibitors

Identifiers

PMID37444415
PMCPMC10340438
OpenAlexW4382062755

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.